You are here

Perspectives in Lung Cancer 2017 - Webcasts on Demand

HOW I OPTIMIZE TREATMENT FOR MY NSCLC PATIENTS WITH ADVANCED AND AGGRESSIVE DISEASE

PILC 2017 About the Speakers

Silvia Novello, MD, PhD

Silvia Novello, MD, PhD

Oncology Department, University of Turin, and Thoracic Oncology Unit, San Luigi Hospital Orbassano, Italy

Silvia Novello is Full Professor of Oncology at the University of Turin and Director of the Thoracic Oncology Unit at the San Luigi Hospital in Orbassano, Italy. Professor Novello received her medical degree from the University of Turin in 1995, and completed a postgraduate course in respiratory medicine “summa cum laude” at the same university in 1999, then achieved a PhD in human oncology and conducted postgraduate research in medical oncology.

 

Professor Novello’s main areas of research are basic and applied clinical research into thoracic malignancies, and gender differences in lung cancer. She has been involved in trials and studies in different clinical stages of lung cancer and pleural mesothelioma, including: supportive care; the treatment of lung cancer in elderly patients; the role of cytokines in thoracic malignancies; the role of oncogenes, anti-oncogenes, and growth factors and their receptors in lung cancer; women and lung cancer; pharmacogenomics and lung cancer; and applied clinical research into aspects of interstitial lung disease.

Professor Novello is a member of American Society of Clinical Oncology (ASCO), and has been a member of the Board of Directors of the International Association for the Study of Lung Cancer (IASLC) since 2011. She is also a member of the National Lung Cancer Partnership (NLCP) Scientific Committee; a member of the IASLC Young Investigators Awards Scientific Committee; a member of the Board of Directors of the Italian Association of Medical Oncology (AIOM); and current President of Women Against Lung Cancer in Europe (WALCE), a non-profit European association founded in Turin, in 2006. She has authored or co-authored over 100 publications in peer-reviewed journals, and book chapters published in scientific volumes. Biography Biography

Fernando López-Ríos, MD, PhD

Fernando López-Ríos, MD, PhD

Targeted Therapies Laboratory, Hospital Universitario HM Sanchinarro, and Universidad CEU San Pablo, Madrid, Spain

Fernando López-Ríos is Director of the Targeted Therapies Laboratory at the Hospital Universitario HM Sanchinarro and Professor of Pathology and Molecular Pathology at Universidad CEU San Pablo in Madrid, Spain. He received his medical and PhD degrees from the Faculty of Medicine at the Universidad Autónoma de Madrid and the Universidad Complutense, respectively, and completed his residency in pathology at the Hospital Universitario 12 de Octubre, all in Madrid. Dr López-Ríos has also been a visiting researcher at the Memorial Sloan Kettering Cancer Center in New York, NY, USA.

His main clinical and research expertise is in cancer biomarker testing, with a special emphasis on lung cancer. 

Joachim G. Aerts, MD, PhD

Joachim G. Aerts, MD, PhD

Thoracic Oncology Department, Erasmus MC, Rotterdam, Netherlands

Joachim Aerts is currently Chair of the Thoracic Oncology Department at the Erasmus University Medical Center (Erasmus MC) in Rotterdam, the Netherlands. He obtained his medical degree and completed his PhD studies both at the Erasmus University in 1996.

His research interests include preventive medicine, pathophysiology, and different treatment options. Professor Aerts performs basic, translational, and clinical studies mainly in lung cancer and mesothelioma, with a special focus on onco-immunology. His group has developed a new concept of immunotherapy in mesothelioma for which he was granted a Horizon 2020 subsidy from the European Union. He is Principal Investigator for several national and international studies.

Professor Aerts is a member of several major scientific societies, including the International Association for the Study of Lung Cancer (IASLC), the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the European Society for Medical Oncology (ESMO). He has authored or co-authored over 120 publications in peer-reviewed journals and books.

Luis Paz-Ares, MD, PhD

Luis Paz-Ares, MD, PhD

Medical Oncology Department, Hospital Universitario 12 de Octubre, and Universidad Complutense, Madrid, Spain

Luis Paz-Ares is currently Chair of the Medical Oncology Department at the Hospital Universitario 12 de Octubre, Associate Professor at the Universidad Complutense, and Head of the Lung Cancer Unit at the CNIO (Spanish National Cancer Research Centre), all in Madrid, Spain. He graduated with a degree in medicine from the Universidad Autónoma de Madrid in 1986, and earned his PhD degree there in 1993. Professor Paz-Ares was a postdoctoral European Society for Medical Oncology (ESMO) research fellow in medical oncology at the Beatson Oncology Centre, University of Glasgow, Scotland (1993–1995), and earned Master’s degrees in clinical pharmacology at the University of Glasgow (1995) and in clinical unit management at the UNED–Fundación Universidad-Empresa, Madrid (2002–2003).

Prior to his current position, Professor Paz-Ares was Chair of the Medical Oncology Department at the University Hospital Virgen del Rocío in Seville, Spain (2007–2014), Head of the Pharmacology Unit and responsible for early clinical studies of thoracic and genito-urinary tumours at the Hospital Universitario 12 de Octubre (1995–1999; 2000–2007), and Visiting Research Fellow in the Prostate Cancer Program at the Dana-Farber Cancer Institute in Boston, MA, USA (1999–2000).

Professor Paz-Ares’ research focuses on lung cancer and the development of new therapeutic strategies, in both the lab and the clinic. He has published more than 240 papers in peer-reviewed journals, including New England Journal of Medicine, The Lancet, The Lancet Oncology, and Journal of Clinical Oncology, and written many book chapters. Professor Paz-Ares is an active member of various scientific societies, including the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), and the International Association for the Study of Lung Cancer (IASLC), and collaborative groups, such as the European Organisation for Research and Treatment of Cancer (EORTC), the Spanish Lung Cancer Group (GECP), and the International Germ Cell Cancer Collaborative Group.

Stay informed

Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Society partner

Made possible by an educational grant from

Please note that Lilly Oncology has no editorial control over the content of this Resource Centre. The Resource Centre and all content therein has been subjected to an independent editorial review.

A few pearls from ELCC 2017

5-8 May 2017, Geneva

by Stefan Zimmermann

A high-level forum where critical issues we face as thoracic oncologists are discussed, and cutting-edge new research is presented. 

Perspectives in Lung Cancer 2017

How I optimize treatment for my NSCLC patients with advanced and aggressive disease


Now available: Webcast on demand


 

Interactive Case Reports

Read more about recent cases from the Journal of Thoracic Oncology. Test your knowledge and answer the questions following the case to get immediate feedback.